Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
What excipients does Abasaglar® (insulin glargine) contain?
Abasaglar contains inactive ingredients as listed below. It is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.
List of excipients
- Zinc oxide
- Hydrochloric acid (for pH adjustment)
- Sodium hydroxide (for pH adjustment), and
- Water for injections.1
1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: 30 January 2022